Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
VIPoma surgery
Introduction
Overview
Overview
Surgery is the mainstay of treatment for VIPoma. Surgery should be considered after initial symptomatic management of VIPoma inoperable cases. Complete surgical resection of the tumor is the only curative treatment for VIPoma. If the tumor cannot be removed completely, surgical debulking may have palliative effect for control of hormonal symptoms.
Surgery
Surgery
- Surgery should be considered after initial symptomatic management of VIPoma inoperable cases.
- Complete surgical resection of the tumor is the only curative treatment for VIPoma.
- The feasibility of surgery depends on the stage of VIPoma at diagnosis.
- If the tumor cannot be removed completely, surgical debulking may have palliative effect for control of hormonal symptoms.
- In nonresectable liver metastases, hepatic TACE (transarterial chemoembolization) is emerging as a new non-emergency therapeutic modality highly successful for control of VIP-related symptoms.
References
References
- ↑ Vinik A. Vasoactive Intestinal Peptide Tumor (VIPoma) [Updated 2013 Nov 28]. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278960/
- ↑ Blaise A, Girardet JL (1969). “[Study of the magnetic properties of siderophilin]”. C R Acad Sci Hebd Seances Acad Sci D. 269 (10): 966–8. PMID 4981295.
- ↑ Dréanic, Johann; Lepère, Céline; El Hajjam, Mostafa; Gouya, Hervé; Rougier, Philippe; Coriat, Romain (2016). “Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?”. Therapeutic Advances in Medical Oncology. 8 (5): 383–387. doi:10.1177/1758834016656495. ISSN 1758-8340.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]